EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients

Domenica Squillaci iD, Annalisa Marcuzzi, Erika Rimondi iD, Guglielmo Riccio, Egidio Barbi, Davide Zanon, Natalia Maximova iD

Life Science Alliance · 2023

DOI: 10.26508/lsa.202201786 ↗

At a glance

Journal article in Life Science Alliance, 2023. Written by Domenica Squillaci and 6 co-authors. Institution: Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. Major MEDLINE topics: Graft vs Host Disease, Bronchiolitis Obliterans Syndrome, Hematopoietic Stem Cell Transplantation. Cited 4 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Health, Institute for Maternal and Child Health IRCCS Burlo Garofolo.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Despite advances in acute graft-versus-host disease (aGVHD) prophylaxis, current pharmacological approaches fail to prevent aGVHD. The protective effect of defibrotide on GVHD incidence and GVHD-free survival has not been sufficiently studied. 91 pediatric patients included in this retrospective study were divided into two groups based on defibrotide use. We compared the incidence of aGVHD and chronic GVHD-free survival between the defibrotide and control groups. The incidence and severity of aGVHD were significantly lower in patients who received defibrotide prophylactic administration than in the control group. This improvement was observed in the liver and intestinal aGVHD. No defibrotide prophylaxis benefit was observed in the prevention of chronic GVHD. The pro-inflammatory cytokine levels were significantly higher in the control group. Our findings suggest that prophylactic administration of defibrotide in pediatric patients significantly reduces the incidence and severity of aGVHD, with a modification of cytokine pattern, both strongly coherent with the protective drug’s action. This evidence adds to pediatric retrospective studies and preclinical data suggesting a possible defibrotide role in this setting.

Subjects

MeSH terms (MEDLINE)

Graft vs Host DiseaseBronchiolitis Obliterans SyndromeHematopoietic Stem Cell TransplantationHumansChildIncidenceRetrospective StudiesCytokines

Substances

Cytokines

Authors and institutions

  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Department of Translational Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.
  • Department of Pediatrics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
  • Department of Pediatrics, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy natalia.maximova@burlo.trieste.it.

ORCID profiles: Domenica Squillaci, Erika Rimondi, Natalia Maximova

Funding

  • Ministry of Health
  • Institute for Maternal and Child Health IRCCS Burlo Garofolo

Cite

APA

Squillaci, D., Marcuzzi, A., Rimondi, E., Riccio, G., Barbi, E., Zanon, D., & Maximova, N. (2023). Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients. Life Science Alliance. https://doi.org/10.26508/lsa.202201786

Vancouver

Squillaci D, Marcuzzi A, Rimondi E, Riccio G, Barbi E, Zanon D, et al. Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients. Life Science Alliance. 2023. doi:10.26508/lsa.202201786

BibTeX
@article{Squillaci2023,
  author = {Squillaci, Domenica and Marcuzzi, Annalisa and Rimondi, Erika and Riccio, Guglielmo and Barbi, Egidio and Zanon, Davide and Maximova, Natalia},
  title = {Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients},
  journal = {Life Science Alliance},
  year = {2023},
  doi = {10.26508/lsa.202201786}
}
Start for free →